Home > Insider Trading > Filing (0001179110-20-001370)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1650664	Editas Medicine Inc.	EDIT	Biological Products, (No Disgnostic Substances) (2836)	464097528

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1682323	Charles Albright	C/O Editas Medicine, Inc. 11 Hurley St. Cambridge MA 02141	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-02-06	11,593	$0.00	32,146	No	4	A	Direct
Common Stock	Disposition	2020-02-07	622	$26.95	31,524	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2020-02-06	69,556	$0.00	69,556	$28.05

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
69,556		2030-02-05	No	4	A	Direct

Footnotes

The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on February 6, 2021 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2024.
The sales reported in this Form 4 were effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represent the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 6, 2020. The sales do not represent a discretionary trade by the Reporting Person.
This transaction was executed in multiple trades at prices ranging from $26.42 to $26.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This option was granted on February 6, 2020 and is scheduled to vest over four years in equal monthly installments beginning on March 6, 2020 through February 6, 2024.